Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial

Overview of attention for article published in Trials, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#25 of 6,384)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 4 news outlets

twitter: 157 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 29 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 6 publications that cite this research output.

6

The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.

Epidemiology, clinical presentation and treatment outcomes in patients with COVID-19 in an ambulatory setting: a cross sectional study during the massive SARS-CoV-2 wave in India

Article in Bioinformation (September 2023)

In-Hospital Receipt of Ivermectin Is Associated With No Benefit in Mortality, Disease Progression, or Length of Stay for Patients With Mild to Moderate COVID-19

Article in Infectious Diseases in Clinical Practice (September 2023)

Ivermectin for COVID-19: The 2022 Update

Article in American Journal of Therapeutics (November 2022)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.